Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 21, 2019. The document serves as a transaction notification regarding dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a regulatory disclosure of specific share transactions and does not contain financial performance data.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details three specific share movements occurring on February 20, 2019:
- Transfer between accounts: Mrs. V A Whyte (Company Secretary) transferred 10,227 Ordinary Shares between accounts for nil consideration.
- Transfer to spouse: Mrs. V A Whyte transferred 17,825 Ordinary Shares to her spouse for nil consideration. The filing explicitly states there was no change in beneficial ownership.
- Receipt from spouse: Mr. Iain Whyte (PCA of Mrs. V A Whyte) received 17,825 Ordinary Shares from his spouse for nil consideration.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the mechanics of the reported share transfers.
Important Facts for Investors to Verify
- Verify that the share transfers between Mrs. V A Whyte and Mr. Iain Whyte resulted in no net change to beneficial ownership.
- Confirm that all transactions were executed for nil consideration (£0.00) as disclosed.
- Note that this filing does not reflect any open market trading or changes in the company's capital structure.